Molecular Partners (NASDAQ:MOLN) AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology. Its lead DARPin candidate, ensovibep, was advanced through clinical trials for the treatment of COVID-19, highlighting the platform’s flexibility in addressing emerging viral threats. In ophthalmology, Molecular Partners is investigating abicipar, a DARPin eye injection designed to extend treatment intervals for patients with neovascular age-related macular degeneration. Additional programs focus on oncology targets, with several preclinical candidates designed to engage multiple cancer‐related pathways simultaneously.
Founded in 2004 as a spin‐off from research at the University of Zurich, Molecular Partners has established collaborations with major pharmaceutical companies to accelerate development and commercialization of its DARPin products. Partnerships with organizations such as Novartis and Roche have enabled access to global development expertise and expanded the reach of its clinical programs. The company maintains operations in Europe and the United States, positioning it to engage with regulators and strategic partners across key markets.
The leadership team is led by Chief Executive Officer Patrick Amstutz, who brings extensive experience in oncology and biologics development. Under his guidance, Molecular Partners has grown from an early‐stage research entity into a publicly traded company listed on the Nasdaq Global Select Market under the symbol MOLN. The company continues to advance its DARPin platform through a combination of internal innovation and collaborative alliances, with the goal of bringing differentiated therapies to patients worldwide.
